Merck to forge ahead with CETP-inhibiting cholesterol med

An independent data-monitoring panel recommended that Merck & Co. ($MRK) continue studying its cholesterol-fighting CETP inhibitor, anacetrapib. The drugmaker had added a futility analysis to the study, dubbed REVEAL, after rival drugmaker Eli Lilly & Co. ($LLY) canned development of its CETP drug evacetrapib. Pfizer ($PFE) and Roche ($RHHBY) had previously given up on their own CETP meds. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

COVID-19 vaccine makers' recent safety pledge continues to increase positive sentiment among Americans, new Harris Poll data say.

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.